Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Loken

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Cancer Cell|November 17, 2023
A longitudinal single-cell atlas of treatment response in pediatric AMLSander Lambo, Diane L Trinh, Rhonda E Ries, et al.
American Journal of Clinical Pathology|October 28, 2011
Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniquesLuise Hartmann, Julie Sanford Biggerstaff, Douglas B Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyLeslie Mortland, Todd A Alonzo, Roland B Walter, et al.
Blood Advances|January 3, 2023
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemiaQuy Le, Thao Tang, Amanda Leonti, et al.
Cytometry. Part B, Clinical Cytometry|July 12, 2019
Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupLaura M Pardo, Andrew P Voigt, Todd A Alonzo, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaQuy Le, Sommer Castro, Thao Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Cancer Cell|November 17, 2023
A longitudinal single-cell atlas of treatment response in pediatric AMLSander Lambo, Diane L Trinh, Rhonda E Ries, et al.
American Journal of Clinical Pathology|October 28, 2011
Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniquesLuise Hartmann, Julie Sanford Biggerstaff, Douglas B Chapman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531Jatinder K Lamba, Lata Chauhan, Miyoung Shin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2019
Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid LeukemiaKatherine Tarlock, Todd A Alonzo, Yi-Cheng Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapyLeslie Mortland, Todd A Alonzo, Roland B Walter, et al.
Blood Advances|January 3, 2023
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemiaQuy Le, Thao Tang, Amanda Leonti, et al.
Cytometry. Part B, Clinical Cytometry|July 12, 2019
Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology GroupLaura M Pardo, Andrew P Voigt, Todd A Alonzo, et al.
Blood Advances|October 20, 2020
Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 reportLisa Eidenschink Brodersen, Robert B Gerbing, M Laura Pardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaQuy Le, Sommer Castro, Thao Tang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2022
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio <i>FLT3</i>/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031Jessica A Pollard, Todd A Alonzo, Robert Gerbing, et al.
Pageof 10